KERX
Income statement / Annual
Last year (2017), Keryx Biopharmaceuticals, Inc.'s total revenue was $60.64 M,
an increase of 89.60% from the previous year.
In 2017, Keryx Biopharmaceuticals, Inc.'s net income was -$163.44 M.
See Keryx Biopharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
FY-2011
|
FY-2010
|
FY-2009
|
FY-2008
|
| Period Ended |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
12/31/2011 |
12/31/2010 |
12/31/2009 |
12/31/2008 |
| Operating Revenue |
$60.64 M |
$31.98 M |
$13.68 M |
$10.83 M |
$7.00 M |
$0.00 |
$5.00 M |
$0.00 |
$25.19 M |
$1.28 M |
| Cost of Revenue |
$25.03 M
|
$40.69 M
|
$6.64 M
|
$495.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$27.00 K
|
| Gross Profit |
$35.61 M
|
-$8.71 M
|
$7.04 M
|
$10.33 M
|
$7.00 M
|
$0.00
|
$5.00 M
|
$0.00
|
$25.19 M
|
$1.26 M
|
| Gross Profit Ratio |
0.59
|
-0.27
|
0.51
|
0.95
|
1
|
0
|
1
|
0
|
1
|
0.98
|
| Research and Development Expenses |
$37.68 M
|
$29.50 M
|
$36.69 M
|
$51.50 M
|
$34.73 M
|
$19.37 M
|
$27.01 M
|
$14.96 M
|
$8.61 M
|
$38.01 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$19.35 M
|
$7.71 M
|
$6.74 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$99.62 M
|
$84.55 M
|
$81.41 M
|
$70.06 M
|
$19.35 M
|
$7.71 M
|
$6.74 M
|
$6.25 M
|
$6.77 M
|
$14.29 M
|
| Other Expenses |
$274.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$137.30 M
|
$114.06 M
|
$118.10 M
|
$121.56 M
|
$54.08 M
|
$27.08 M
|
$33.75 M
|
$21.22 M
|
$15.38 M
|
$52.30 M
|
| Cost And Expenses |
$162.33 M
|
$154.75 M
|
$124.75 M
|
$122.05 M
|
$54.08 M
|
$27.08 M
|
$33.75 M
|
$21.22 M
|
$15.38 M
|
$52.32 M
|
| Interest Income |
$707.00 K
|
$698.00 K
|
$472.00 K
|
$290.00 K
|
$351.00 K
|
$52.00 K
|
$159.00 K
|
$148.00 K
|
$315.00 K
|
$1.35 M
|
| Interest Expense |
$62.97 M
|
$34.21 M
|
$11.36 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$352.00 K
|
$0.00
|
| Depreciation & Amortization |
$1.92 M
|
$1.70 M
|
$1.07 M
|
$185.00 K
|
$54.00 K
|
$35.00 K
|
$47.00 K
|
$60.00 K
|
$92.00 K
|
$111.00 K
|
| EBITDA |
-$99.77 M |
-$121.06 M |
-$111.10 M |
-$111.04 M |
-$47.03 M |
-$28.71 M |
-$28.70 M |
-$21.77 M |
$9.82 M |
-$50.93 M |
| EBITDA Ratio |
-1.65
|
-3.79
|
-8.12
|
-10.26
|
-6.72
|
0
|
-5.74
|
0
|
0.39
|
-39.7
|
| Operating Income Ratio |
-1.68
|
-3.84
|
-8.12
|
-10.28
|
-6.73
|
0
|
-5.75
|
0
|
0.39
|
-39.78
|
| Total Other Income/Expenses Net |
-$61.98 M
|
-$38.25 M
|
-$11.99 M
|
$411.00 K
|
$351.00 K
|
$1.72 M
|
$380.00 K
|
$764.00 K
|
$667.00 K
|
-$1.67 M
|
| Income Before Tax |
-$163.68 M
|
-$161.02 M
|
-$123.06 M
|
-$110.82 M
|
-$46.73 M
|
-$25.36 M
|
-$28.37 M
|
-$20.45 M
|
$10.49 M
|
-$52.71 M
|
| Income Before Tax Ratio |
-2.7
|
-5.03
|
-9
|
-10.24
|
-6.68
|
0
|
-5.67
|
0
|
0.42
|
-41.08
|
| Income Tax Expense |
-$235.00 K
|
$80.00 K
|
$90.00 K
|
$700.00 K
|
-$351.00 K
|
-$4.36 M
|
$0.00
|
-$884.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$163.44 M
|
-$161.10 M
|
-$123.15 M
|
-$111.52 M
|
-$46.38 M
|
-$22.72 M
|
-$28.12 M
|
-$20.33 M
|
$10.49 M
|
-$52.88 M
|
| Net Income Ratio |
-2.7
|
-5.04
|
-9
|
-10.3
|
-6.63
|
0
|
-5.62
|
0
|
0.42
|
-41.22
|
| EPS |
-1.43 |
-1.52 |
-1.19 |
-1.23 |
-0.57 |
-0.32 |
-0.42 |
-0.34 |
0.21 |
-1.18 |
| EPS Diluted |
-1.43 |
-1.52 |
-1.19 |
-1.23 |
-0.57 |
-0.32 |
-0.42 |
-0.34 |
0.21 |
-1.18 |
| Weighted Average Shares Out |
$114.51 M
|
$105.85 M
|
$103.90 M
|
$91.00 M
|
$81.01 M
|
$71.63 M
|
$67.37 M
|
$58.99 M
|
$49.94 M
|
$44.90 M
|
| Weighted Average Shares Out Diluted |
$114.51 M
|
$105.85 M
|
$103.90 M
|
$91.00 M
|
$81.01 M
|
$71.63 M
|
$67.37 M
|
$58.99 M
|
$50.50 M
|
$44.90 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
